2019
1188PD Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis
Catenacci D, Park H, Uronis H, Kang Y, Ng M, Enzinger P, Lee K, Lim K, Gold P, Lacy J, Park S, Huber K, Wynter-Horton A, Nordstrom J, Wu T, Wigginton J, Baughman J, Rosales M, Davidson-Moncada J, Bang Y. 1188PD Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis. Annals Of Oncology 2019, 30: v484-v485. DOI: 10.1093/annonc/mdz253.014.Peer-Reviewed Original ResearchMedian progression-free survivalMedian overall survivalGenentech/RocheBristol-Myers SquibbGastroesophageal adenocarcinomaPD-L1Prime TherapeuticsOno PharmaceuticalOS ratesEMD SeronoMerck SeronoAstellas PharmaDaiichi SankyoGilead SciencesChemotherapy-free regimenPD-L1 CPSProgression-free survivalTreatment of patientsCancer ptsGuardant HealthMedian followMedian PFSCheckpoint inhibitorsExpansion cohortAcceptable tolerability
2011
Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience.
Smyth E, Enzinger P, Li J, Vincitore M, Lacy J, El-Rayes B, Kunz P, Ford J, Robinson E, Kelsen D, Shah M. Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience. Journal Of Clinical Oncology 2011, 29: 4056-4056. DOI: 10.1200/jco.2011.29.15_suppl.4056.Peer-Reviewed Original ResearchGastroesophageal adenocarcinomaAdvanced gastroesophageal adenocarcinoma